Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | SLC25A20 | O43772 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.76 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.76 |
| ▸ | GMNN | O75496 | 3/20 | 0.76 |
| ▸ | LMNA | P02545 | 3/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Palmitoyl-Carnitine SCHEMBL115183 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ASLC25A20TP53 | |
| SCHEMBL288673 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ASLC25A20TP53 | |
| SCHEMBL19182624 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ASLC25A20TP53 | |
| SCHEMBL8050598 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ASLC25A20TP53 | |
| SCHEMBL288242 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ASLC25A20TP53 | |
| SCHEMBL17164609 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ASLC25A20TP53 | |
| SCHEMBL25373354 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ASLC25A20TP53 | |
| Palmitoyl-Carnitine SCHEMBL187668 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ASLC25A20TP53 | |
| Octanoylcarnitine SCHEMBL2915508 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ASLC25A20TP53 | |
| SCHEMBL188470 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ASLC25A20TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 458 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125683-A1 | TREATMENT OF CANCERS HAVING A DRUG-RESISTANT MESENCHYMAL CELL STATE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-05-07 | — | — | US | claimed |
| US-12292445-B2 | Methods of selecting subjects for treatment with metabolomic modulators | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-05-06 | — | — | US | claimed |
| WO-2024192141-A1 | TREATMENT OF CANCERS HAVING A DRUG-RESISTANT MESENCHYMAL CELL STATE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-09-19 | — | — | WO | claimed |
| US-12050228-B2 | Automated sample quality assessment | METABOLON, INC. (US) | 2024-07-30 | — | — | US | claimed |
| US-20240230657-A1 | SIMPLIFIED QUANTITATIVE ANALYSIS USING SUBSTRATES WITH PRE-LOADED STANDARDS | CAPITAINER AB (SE) | 2024-07-11 | — | — | US | claimed |
| US-11906510-B2 | Metabolic profiling by reverse-phase/ion-exchange mass spectrometry | STANFORD JUNIOR UNIVERSITY (US) | 2024-02-20 | — | — | US | claimed |
| CN-116660543-A | Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof | 中国人民解放军陆军军医大学第一附属医院 | 2023-08-29 | — | — | CN | claimed |
| US-11698361-B1 | Method of processing a biological sample | Metabolomic Diagnostics Limited (IE) | 2023-07-11 | — | — | US | claimed |
| CN-111505099-B | Diagnostic markers for NASH and uses thereof | 上海市普陀区中心医院 | 2023-07-04 | — | — | CN | claimed |
| US-20230149338-A1 | DIAGNOSIS AND TREATMENT OF ADDICTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-05-18 | — | — | US | claimed |
| EP-2468273-A2 | Method to reduce oxidative damage and improve mitochondrial efficiency | Accera, Inc. (US) | 2012-06-27 | — | — | EP | claimed |
| US-20100116691-A1 | BIOSENSOR FOR CONTINUOUS MONITORING OF METABOLITES AND PROTEINS AND METHODS OF MANUFACTURE THEREOF | UNIVERSITY OF CONNECTICUT (US) | 2010-05-13 | — | — | US | claimed |
| EP-0215697-B1 | ACYLCARNITINES AS ABSORPTION-ENHANCING AGENTS FOR DRUG DELIVERY THROUGH MUCOUS MEMBRANES OF THE NASAL, BUCCAL, SUBLINGUAL AND VAGINAL COMPARTMENTS | MERCK & CO. INC. (US) | 1992-03-25 | — | — | EP | claimed |
| US-4963525-A | POLYPEPTIDES | MERCK & CO., INC. (US) | 1990-10-16 | — | — | US | claimed |
| EP-0162764-B1 | COMPOSITION AND METHOD FOR ENHANCING ABSORPTION OF DRUGS FROM GASTROINTESTINAL TRACT USING ACYLCARNITINES | MERCK & CO. INC. (US) | 1989-08-09 | — | — | EP | claimed |
| US-4847298-A | DOPA COMPOUNDS OR ANTIBIOTICS | MERCK & CO., INC. (US) | 1989-07-11 | — | — | US | claimed |
| US-4731360-A | Acylcarnitines as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal compartments | MERCK & CO., INC. (US) | 1988-03-15 | — | — | US | claimed |
| EP-0215697-A2 | Acylcarnitines as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal compartments | MERCK & CO. INC. (US) | 1987-03-25 | — | — | EP | claimed |
| EP-0162764-A1 | Composition and method for enhancing absorption of drugs from gastrointestinal tract using acylcarnitines | MERCK & CO. INC. (US) | 1985-11-27 | — | — | EP | claimed |
| US-4537772-A | Enhancing absorption of drugs from gastrointestinal tract using acylcarnitines | MERCK & CO., INC. (US) | 1985-08-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149338-A1 | DIAGNOSIS AND TREATMENT OF ADDICTION | CRAT, OPRK1, OPRD1 | MAPT 489/4885MEN1 4830/4885KMT2A 176/4885 |
| US-20260125683-A1 | TREATMENT OF CANCERS HAVING A DRUG-RESISTANT MESENCHYMAL CELL STATE | ACTR2, RPS6KB2, EPB41L2 | MAPT 4006/4885MEN1 2877/4885KMT2A 1596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.